<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000200145</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000200015</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Miastenia gravis secundaria a pembrolizumab]]></article-title>
<article-title xml:lang="en"><![CDATA[Miastenia gravis secondary to pembrolizumab]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Minardi]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Italiano de Buenos Aires Servicio de Farmacia Ambulatoria ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Universitario del Hospital Italiano Departamento de Farmacología y Toxicología ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>145</fpage>
<lpage>146</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000200145&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000200145&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000200145&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN En los últimos años el avance de terapias dirigidas para tratamiento de enfermedades oncológicas ha ido en aumento exponencial. En este contexto, un nuevo grupo de anticuerpos monoclonales, que inhiben el receptor de muerte celular programada 1 han surgido como una efectiva primera línea de tratamiento para determinadas neoplasias. Pembrolizumab, un anticuerpo monoclonal humanizado, es una opción estándar para el tratamiento de enfermedades malignas avanzadas o metastásicas tales como mieloma múltiple pero, en lo que a seguridad respecta, investigaciones clínicas han descubierto diversos, impredecibles y graves eventos adversos relacionados con el sistema inmunológico. Se describe caso de un paciente oncológico con sospecha de miastenia gravis luego de haber recibido pembrolizumab 200 mg cada 3 semanas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY In recent years the development of anti-cancer target drugs therapy has been increasing exponentially. In this context, a monoclonal antibody group's which inhibits the programmed cell death 1 receptor, has emerged as an effective frontline of treatment of certain neoplasms. Pembrolizumab, a humanized monoclonal antibody, is a standard option for the treatment of advanced and metastatic malignancies like multiple myeloma. However, clinical research has uncovered diverse, unpredictable and serious immune related adverse events that raise concerns regarding it's safety. Here we describe the case of an oncology patient with a suspected myasthenia gravis after receiving pembrolizumab 200 mg every 3 weeks.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Miastenia gravis]]></kwd>
<kwd lng="es"><![CDATA[pembrolizumab]]></kwd>
<kwd lng="es"><![CDATA[receptor de muerte celular programada 1]]></kwd>
<kwd lng="en"><![CDATA[Myasthenia gravis]]></kwd>
<kwd lng="en"><![CDATA[pembrolizumab]]></kwd>
<kwd lng="en"><![CDATA[programmed cell death 1 receptor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shindo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshimura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kuramasu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Oga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hazama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tamada]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yagita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2015</year>
<volume>35</volume>
<page-range>129-36</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ritprajak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Azuma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intrinsic and extrinsic control of expression of then immunoregulatory molecule PDL1 in epithelial cells and squamous cell carcinoma]]></article-title>
<source><![CDATA[Oral Oncol]]></source>
<year>2015</year>
<volume>51</volume>
<page-range>221-8</page-range><publisher-name><![CDATA[Francisco LM, Sage PT, Sharpe]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardoll]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The blockade of immune checkpoints in cancer immunotherapy]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2012</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>252-64</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Goldinger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurological, respiratory, musculoskeletal, cardiac and ocular side- effects of anti-PD-1 therapy]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>60</volume>
<page-range>210-25</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilhus]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myasthenia Gravis]]></article-title>
<source><![CDATA[N Engl Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>2570-81</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<collab>Merck &amp; Co., Inc.</collab>
<source><![CDATA[Keytruda (pembrolizumab) [packageinsert]]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Whitehouse, NJ ]]></publisher-loc>
<publisher-name><![CDATA[Merck &amp; Co., Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Tykodi]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[LQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and activity of anti-PD-L1 antibody in patients with advanced cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<page-range>2455</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2016</year>
<volume>54</volume>
<page-range>157-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myasthenia gravis exacerbation associated with pembrolizumab]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2016</year>
<volume>54</volume>
<page-range>506-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
